Structural Requirements for Glycosaminoglycan Recognition by the Lyme Disease Spirochete, Borrelia burgdorferi†

AUTOR(ES)

Leong, John M.

FONTE

American Society for Microbiology

RESUMO

Borrelia burgdorferi, the Lyme disease agent, binds glycosaminoglycans (GAGs) such as heparin, heparan sulfate, and dermatan sulfate. Heparin or heparan sulfate fractions separated by size or charge were tested for their ability to inhibit attachment of B. burgdorferi to Vero cells. GAG chains of increasing length and/or charge showed increasing inhibitory potency, and detectable heparin inhibition of bacterial binding required a minimum of 16 residues. The ability of a given heparin fraction to inhibit binding to Vero cells was strongly predictive of its ability to inhibit hemagglutination, suggesting that hemagglutination reflects the capacity of B. burgdorferi to bind to GAGs.

Documentos Relacionados

• Hemagglutination and proteoglycan binding by the Lyme disease spirochete, Borrelia burgdorferi.
• Absence of lipopolysaccharide in the Lyme disease spirochete, Borrelia burgdorferi.
• rRNA gene organization in the Lyme disease spirochete, Borrelia burgdorferi.
• Temperature-related differential expression of antigens in the Lyme disease spirochete, Borrelia burgdorferi.
• Complete nucleotide sequence of a circular plasmid from the Lyme disease spirochete, Borrelia burgdorferi.